Literature DB >> 7894205

Hypertonic saline infusion induces activation of the lymphocyte Na+/H+ antiport and cytosolic alkalinization in healthy human subjects.

R Düsing1, S Leibhammer, G Hoffmann, H Vetter, W Siffert.   

Abstract

The Na+/H+ antiport is a membrane transport protein that extrudes intracellular protons in exchange for extracellular sodium. Some details of its physiological and pathophysiological role remain poorly defined. Experimental evidence suggests that the antiporter is involved in the regulation of cell volume. In the present study, we therefore investigated the activity of the lymphocyte Na+/H+ antiport in nine healthy volunteers following acute hypertonic (2.5%) saline infusion (4 mmol NaCl/kg over 120 min). Antiport activity was measured after acidifying the cells with Na+ propionate (5-40 mM) using the fluorescent dye bis-carboxyethyl carboxyfluorescein. Hypertonic saline induced significant increases in plasma osmolality (308.4 +/- 2.3 vs. 293.5 +/- 2.7 mOsm/kg; P < 0.01), serum Na+ (150.8 +/- 3.7 vs. 138.9 +/- 0.5 mmol/kg; P < 0.01), and Cl- concentrations (118.0 +/- 3.9 vs. 101.1 +/- 1.0 mmol/kg; P < 0.01). Extracellular hypertonicity was followed by a stimulated activity of the lymphocyte Na+/H+ antiport with an increase in the apparent Vmax values from 2.44 +/- 0.16 to 3.27 +/- 0.34 10(-3) s-1 (P < 0.01) and a slight rise in pK, from 6.81 +/- 0.03 to 6.87 +/- 0.03 (P < 0.05) after hypertonic saline. In addition to antiport activation, cytosolic alkalinization was observed with cytosolic pH values averaging 6.90 +/- 0.02 before and 6.99 +/- 0.02 (P < 0.01) after hypertonic saline. Our results show for the first time that acute extracellular hypertonicity in man due to hypertonic NaCl loading is associated with a stimulated lymphocyte Na+/H+ antiport activity and cytosolic alkalinization.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7894205     DOI: 10.1007/bf00190734

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  17 in total

1.  Dilution acidosis and contraction alkalosis: review of a concept.

Authors:  S Garella; B S Chang; S I Kahn
Journal:  Kidney Int       Date:  1975-11       Impact factor: 10.612

2.  THE MECHANISM OF ACIDOSIS PRODUCED BY HYPEROSMOTIC INFUSIONS.

Authors:  R W WINTERS; P R SCAGLIONE; G G NAHAS; M VEROSKY
Journal:  J Clin Invest       Date:  1964-04       Impact factor: 14.808

Review 3.  Mechanisms of regulation of the Na+/H+ exchanger.

Authors:  S Grinstein; A Rothstein
Journal:  J Membr Biol       Date:  1986       Impact factor: 1.843

4.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

5.  Effect of isotonic volume expansion on extracellular bicarbonate stores in normal dogs.

Authors:  S Garella; A H Tzamaloukas; J A Chazan
Journal:  Am J Physiol       Date:  1973-09

6.  Acid-base and electrolyte changes induced by acute isotonic saline infusion in the nephrectomized dog.

Authors:  B J Rosenbaum; D L Makoff; M H Maxwell
Journal:  J Lab Clin Med       Date:  1969-09

7.  Hypertonic expansion: acid-base and electrolyte changes.

Authors:  D L Makoff; J A da Silva; B J Rosenbaum; S E Levy; M H Maxwell
Journal:  Am J Physiol       Date:  1970-04

8.  The mammalian Na+/H+ exchanger gene family--initial structure/function studies.

Authors:  M Tse; S Levine; C Yun; S Brant; J Pouyssegur; M Donowitz
Journal:  J Am Soc Nephrol       Date:  1993-10       Impact factor: 10.121

Review 9.  Membrane sodium-proton exchange and primary hypertension.

Authors:  D Rosskopf; R Düsing; W Siffert
Journal:  Hypertension       Date:  1993-05       Impact factor: 10.190

10.  The lymphocyte Na+/H+ antiport: activation in primary hypertension and during chronic NaCl-loading.

Authors:  B O Göbel; G Hoffmann; M Ruppert; K O Stumpe; H Vetter; W Siffert; R Düsing
Journal:  Eur J Clin Invest       Date:  1994-08       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.